secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001104659-25-003777
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell receives Nasdaq delisting notice for failure to meet MVLS minimum
--------------------------------------------------------------------------------

- Nasdaq notified BCLI on Jan 15, 2025 that it failed to regain compliance with the $35M MVLS requirement by the Jan 14 deadline.
- Unless BCLI appeals by Jan 22, 2025, its common stock will be delisted from the Nasdaq Capital Market at open on Jan 24, 2025.
- Company intends to appeal the delisting determination, but no assurance of success or continued listing.
- BCLI previously received a 180-day cure period on July 18, 2024 to meet the MVLS rule (Nasdaq 5550(b)(2)).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925003777/0001104659-25-003777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925003777/tm253461d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-003777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer